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The increasing evidence supporting a role for B cells in the pathogenesis of multiple sclerosis prompted us to investigate the
inﬂuence of known susceptibility variants on the surface expression of co-stimulatory molecules in these cells. Using ﬂow cytometry
we measured surface expression of CD40 and CD86 in B cells from 68 patients and 162 healthy controls that were genotyped for
the multiple sclerosis associated single nucleotide polymorphisms (SNPs) rs4810485, which maps within the CD40 gene, and
rs9282641, which maps within the CD86 gene. We found that carrying the risk allele rs4810485*T lowered the cell-surface
expression of CD40 in all tested B cell subtypes (in total B cells P45.10  105 in patients and 44.09  106 in controls), while
carrying the risk allele rs9282641*G increased the expression of CD86, with this effect primarily seen in the naı¨ve B cell subset
(P = 0.048 in patients and 5.38  105 in controls). In concordance with these results, analysis of RNA expression demonstrated
that the risk allele rs4810485*T resulted in lower total CD40 expression (P = 0.057) but with an increased proportion of alter-
native splice-forms leading to decoy receptors (P = 4.00  107). Finally, we also observed that the risk allele rs4810485*T was
associated with decreased levels of interleukin-10 (P = 0.020), which is considered to have an immunoregulatory function down-
stream of CD40. Given the importance of these co-stimulatory molecules in determining the immune reaction that appears in
response to antigen our data suggest that B cells might have an important antigen presentation and immunoregulatory role in the
pathogenesis of multiple sclerosis.
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Abbreviations: EAE = experimental autoimmune encephalomyelitis; MFI = mean ﬂuorescence intensity; PBMC = peripheral blood
mononuclear cells; SNP = single nucleotide polymorphism
Introduction
Multiple sclerosis is an autoimmune disease of the central
nervous system that is characterized pathologically by in-
ﬂammation, demyelination and axonal loss. Genome-wide
association studies have enabled the identiﬁcation of 11
human leukocyte antigen (HLA) and 110 non-HLA genetic
risk factors (The Australia and New Zealand Multiple
Sclerosis Genetics Consortium, 2009; Patsopoulos et al.,
2011; The International Multiple Sclerosis Genetics
Consortium and The Wellcome Trust Case Control
Consortium 2, 2011; The International Multiple Sclerosis
Genetics Consortium, 2013; Moutsianas et al., 2015).
Collectively these variants explain 28% of heritability to
the disease (The International Multiple Sclerosis Genetics
Consortium, 2013), but to date translating these associations
into meaningful biology has proven to be difﬁcult (Goris
et al., 2012; Sawcer et al., 2014). The associated regions
are heavily enriched for genes with known immunological
function, pointing to a primary role of the adaptive immune
system in the pathogenesis of the disease (The International
Multiple Sclerosis Genetics Consortium and The Wellcome
Trust Case Control Consortium 2, 2011; The International
Multiple Sclerosis Genetics Consortium, 2013; Dendrou
et al., 2015). Because of their limited contribution to the
induction of experimental autoimmune encephalomyelitis
(EAE) in mouse models, the contribution of B cells to mul-
tiple sclerosis development has long been overshadowed by
investigation into T cells. Recent data on the role of B cells
in the pathogenesis of multiple sclerosis (Schubert et al.,
2015; Dooley et al., 2016), and the highly promising results
of B cell directed therapies (Hauser et al., 2017; Montalban
et al., 2017) in the disease have challenged the earlier T cell
paradigm. Several of the multiple sclerosis risk single nucleo-
tide polymorphisms (SNPs) are located in or near genes for
co-stimulatory molecules (The Australia and New Zealand
Multiple Sclerosis Genetics Consortium, 2009; The
International Multiple Sclerosis Genetics Consortium and
The Wellcome Trust Case Control Consortium 2, 2011;
The International Multiple Sclerosis Genetics Consortium,
2013), playing a role in B cells in the context of antigen
presentation, such as CD40 and CD86. Current evidence
suggests that most genetic risk factors for complex disease
do not alter protein function, but rather exert their effects by
changing the expression of genes in immune cells (Maurano
et al., 2012; Raj et al., 2014; Sawcer et al., 2014). In this
study we assessed surface expression of key co-stimulatory
molecules (CD40 and CD86) on B cell subtypes in patients
with untreated multiple sclerosis and healthy control sub-
jects, and correlated our ﬁndings with genotype at associated
SNPs rs4810485 and rs9282641.
Materials and methods
Study population
All cases and controls gave written informed consent and the
study was approved by the Ethics Committee of the University
Hospitals Leuven (ML4733, cases) and the University of
Cambridge (REC-11/33/0007, controls).
Cases
A study population of 68 unrelated patients of Caucasian
descent fulﬁlling McDonald criteria for multiple sclerosis
was included at the outpatient Department of Neurology of
the University Hospitals Leuven. Demographic and clinical
data were collected through a questionnaire and inspection
of medical records (Supplementary Table 1). All patients
were untreated at the time of sampling with no history of
cancer, immunosuppressive treatments or antibiotics, anti-
allergy or anti-inﬂammatory treatment in the week prior to
sampling.
Control subjects
We studied 162 healthy volunteers recruited from the
Cambridge BioResource and selected on the basis of their
rs9282641 genotype. The date of attendance of the healthy
controls was randomized with respect to genotype and all
data collection and sample testing was undertaken fully
blinded to genotype.
Immunophenotyping
Leuven
Heparinized blood was collected from patients and rested at
18C for 2–4 h prior to isolation of peripheral blood mononu-
clear cells (PBMCs) using lymphocyte separation medium (LSM,
MP Biomedicals). PBMCs were frozen in 10% dimethyl sulfoxide
(Sigma) and stored at 80C prior to analysis. PBMCs were
processed in different batches at four different time points.
Cell surface expression in speciﬁc cell subtypes was examined
using a B cell panel (CD19-BV510, CD27-AF-700, CD38-APC,
CD24-BV421, IgM-PE, IgD-APC-Cy7, CD40-PE-Cy-7 and
CD86-PE-CF594). Six B cell populations were measured using
the following gating strategy: total B (CD19+), transitional
(CD19+CD24hiCD38hi), naı¨ve (CD19+CD27), non-switched
memory (CD19+CD27+IgD+), class-switched memory
(CD19+CD27+IgD) and plasmablasts (CD19+CD24CD38hi).
Expression of CD40 on non-B cells was performed using
CD19CD40+ cells. Based on CD40 expression patterns and
forward scatter/side scatter analysis, these cells are largely mye-
loid in origin. Expression of CD40 and CD86 was measured as
percentage of positive cells and as mean and, where appropriate
mode, of ﬂuorescence intensity (MFI) across positive cells for
each cell type. Representative ﬂuorescence-activated cell sorting
(FACS) plots are shown in Supplementary Figs 1 and 2.
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Cambridge
Heparinized venous blood was collected of healthy controls re-
cruited from the Cambridge BioResource (http://www.cambridge-
bioresource.group.cam.ac.uk), all samples were collected in the
morning and were fully processed within 4h. PBMCs were iso-
lated by density gradient centrifugation using Ficoll-Paque
TM
PLUS
(GE Healthcare). Cell surface expression of CD40 and CD86
in speciﬁc cell subtypes was examined using a B cell panel
(CD19-PerCP-Cy5.5, CD27-PE-Cy7, IgD-V500, CD40-FITC,
and CD86-APC) deﬁning total (CD19+), naı¨ve (CD19+CD27),
non-switched memory (CD19+CD27+IgD+) and class-switched
memory (CD19+CD27+IgD) cell types. Expression of CD86
was also assessed in monocytes using a second panel (CD14-
APC-H7, CD16-PE, HLA-DR-V500, CD80-FITC, and CD86-
APC), deﬁning total (CD14+), classical (CD14hiCD16),
intermediate (CD14hiCD16+) and non-classical (CD14loCD16+)
monocytes. Sample-speciﬁc isotype controls were determined for
both CD86 and CD40. Ultimately, we were able to obtain isotype
controlled data for CD86 and CD40 in B cells from 135 subjects
and for CD86 in monocytes from 144 subjects. Expression of
CD40 and CD86 was measured both as a percentage of cells
and as MFI ratio within positive cells. The latter corresponds
with the ratio between the observed geometric mean ﬂuorescence
and the geometric mean ﬂuorescence in the corresponding sample
speciﬁc isotype control. Representative FACS plots are shown in
Supplementary Figs 3 and 4.
Genotyping
SNP genotyping was undertaken using predesigned assays for the
CD40 SNP rs4810485 (C_1260190_10) (cases and controls) and
the CD86 SNP rs9282641 (C_30239585_20) (cases), run on a
7300 Sequence Detection Instrument or Quantstudio 7K Flex
System (Thermo Fisher). For healthy controls, rs9282641 geno-
types were provided by the Cambridge BioResource.
Gene expression
Leuven
RNA was extracted from total PBMCs and reverse transcribed
using a high-capacity cDNA reverse transcription kit (Thermo
Fisher). Droplet digital PCR (Bio-Rad) was performed using
50 ng cDNA according to the manufacturer’s instructions
with predesigned gene expression assays (Thermo Fisher) for
total CD40 (Hs00374176_m1, spanning exon 1-2), CD40
without exon 6 (Hs01008251_m1, spanning exon5-7) and
housekeeping gene POLR2A (Hs00172187_m1) or custom
assays (sequence available upon request) for CD40 without
exon 5 (spanning exon 4-6) and without exon 5 and 6 (span-
ning exon 4-7). Relative quantity of the CD40 splice forms
versus POLR2A and of the alternative splice forms versus
total CD40 was measured with QuantaSoftTM v1.4 (Bio-Rad).
Cambridge
From each control sample, we collected CD14+ and CD19+ cells
using magnetic activated cell sorting (Miltenyi Biotec); by ﬂow
cytometry we achieved purities in excess of 97% and 87%, re-
spectively. RNA was extracted from these separated cells using
TRIzol Reagent (Life Technologies). A maximum of 1mg of
RNA was reverse transcribed using SuperScript III First-Strand
Synthesis System (Life Technologies) with a 50:50 mixture of
random Oligo(dT) primers. CD86 mRNA transcript expression
was then determined using TaqManTM on the QuantStudioTM
7K Flex System. The primers used to detect mRNA expression of
transcripts (i) containing the transmembrane domain; (ii) lacking
the transmembrane domain; (iii) starting with the ﬁrst exon;
and (iv) starting with the second exon are provided in
Supplementary Fig. 5. A reference gene, TATA-box binding pro-
tein (TBP), was used to establish the relative expression of each
transcript using the standard curve method.
Cytokine analyses
Plasma or serum samples were collected for patients and controls
and stored at 80C for subsequent analysis. In healthy controls
soluble CD86 serum levels were quantiﬁed using the sandwich
enzyme linked immunosorbent assay (ELISA) with a predesigned
CD86 Human ELISA Kit (Abcam) with serum diluted 1:20, and
plates were read using the Bio-Rad Plate Reader model 680. In
patients circulating plasma levels of B cell activation factor
(BAFF) were measured using a human BAFF Quantikine
ELISA (R&D Systems), and cytokines IFN-g, IL-10, IL-12p70,
IL-2, IL-4, IL-6, IL-8 and TNF-a were quantiﬁed in plasma by
electrochemiluminescence immunoassay using the V-Plex Human
Proinﬂammatory Panel Meso Scale Discovery (MSD) plates. All
MSD measurements on 68 untreated multiple sclerosis patients
were done on the same 96-well plate including an eight-point
standard curve (1/4 dilutions starting from 370pg/ml, with the
eighth point being blank) (Supplementary Fig. 6). Values below
the detection limit (0.03pg/ml) are set at the detection limit
for analysis. For a subset of 17 untreated multiple sclerosis
patients, IL-10 levels were additionally measured from a
second sample obtained 3 years [standard deviation (SD)
0.5 years] previously.
Statistical analysis
Linear regression models in R v3.3.2 and Plink v1.07 included
the phenotype (immunological or gene expression variable) as
function of genotype assuming an allele dosage model (number
of risk alleles as 0, 1 or 2). In the Leuven study population
immunophenotyping batch was taken into account as a cov-
ariate. Despite the extensive correlation between many of the
assessed variables, we applied a conservative correction factor
for multiple testing of 80 [based on the number of B cell and
monocyte subsets considered, and the fact that both per cent
positive cells and MFI (ratio) were considered for each SNP in
patients and controls]. Applying this correction factor gener-
ated a corrected signiﬁcance threshold P-value of 0.00056 for
the cellular variables. In our follow-up experiments to unravel
the mechanism of action (RNA expression and cytokine ana-
lysis), a nominal signiﬁcance threshold (P = 0.05) was applied.
Results
CD40 and CD86 genotype correlates
with cell surface expression
In order to study the effect of multiple sclerosis risk var-
iants mapping within the genes for CD40 (rs4810485) and
CD86 (rs9282641) on the surface expression of these
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co-stimulatory molecules in B cells we collected PBMCs
from 68 untreated multiple sclerosis patients and 162
healthy volunteers (Supplementary Table 1). Using ﬂow
cytometry we then deﬁned B cell subtypes and measured
the percentage of cells that were positive for each molecule
together with the surface expression levels on positive cells
within deﬁned subgroups (naı¨ve, non-switched memory,
switched memory, transitional, and plasmablasts in cases,
and just the ﬁrst four subtypes in controls). Cases and
controls were processed independently at two sites, cases
in Leuven and controls in Cambridge.
We observed notable differences in the expression of these
co-stimulatory receptors across the tested B cell subsets in
untreated multiple sclerosis patients (Supplementary Fig. 7).
Transitional B cells (CD19+CD24hiCD38hi) have the highest
expression levels of CD40 in untreated multiple sclerosis
patients, while plasmablasts (CD19+CD24CD38hi) have the
lowest CD40 MFI as well as the lowest percentage of CD40-
positive cells. The percentage of CD86-positive cells increases
with B cell activation state from transitional and naı¨ve over
memory B cells to plasmablasts. Overall, there was no net
effect of the multiple sclerosis risk SNPs on the B cell subset
frequencies in patients or controls (data not shown).
We observed highly signiﬁcant associations between CD40
expression and the rs4810485 genotype in all B cell subsets
(patients: P4 5.10  105, controls P4 4.09  106), with
each copy of the multiple sclerosis risk allele rs4810485*T
corresponding to lower CD40 cell surface expression levels
(Figs 1 and 2). The percentage CD40-positive cells approx-
imates 100% across most cell subsets with little variation,
although a trend in the same direction as for MFI was
observed in cases and controls (Supplementary Figs 8 and
9). In untreated multiple sclerosis patients, the myeloid cell
subset showed a trend for decreased CD40 MFI
(P = 0.0024) (Supplementary Fig. 10). This association is in
the same direction as for B cells, but does not survive multi-
ple testing. Importantly, signiﬁcance levels are three to four
orders of magnitude smaller and the effect size is about half
compared to B cells in the same study population.
The CD86 SNP rs9282641 has a relatively low minor allele
frequency (9%), and therefore healthy controls were selected
from the Cambridge BioResource on the basis of genotype in
order to ensure a more uniform distribution across genotypes.
In these healthy controls, we found that the multiple sclerosis
risk allele rs9282641*G is associated with a higher percen-
tage of CD86-positive B cells, primarily in naı¨ve B cells
(CD19+CD27) (P = 5.38  105) (Fig. 3). These associa-
tions are conﬁrmed in multiple sclerosis patients, where asso-
ciations were observed in three of six cell types, i.e. total B
cells (CD19+), naı¨ve B cells (CD19+CD27) and class-
switched memory B cells (CD19+CD27+IgD) (P4 0.048)
(Fig. 4). Of note, since the patients are a population-based
study sample, individuals homozygous for the minor allele are
few in number and the power is thereby reduced in compar-
ison to the genotype-enriched study population of controls.
Concerning CD86 MFI, nominally signiﬁcant associations
were observed for all B cell subsets in controls and for
switched B cells in cases, but these trends did not survive
correction for multiple testing (Supplementary Figs 11 and
12). As CD86 is expressed on antigen-presenting cells, includ-
ing not only B cells but also monocytes, we additionally
measured surface expression of CD86 in three monocyte
subtypes in the healthy control individuals (classical
CD14hiCD16, non-classical CD14loCD16+ and intermediate
Figure 1 Association of the CD40 SNP rs4810485 with B cell surface expression of CD40 in healthy controls (n = 135). MFI ratio
of CD40 on CD40-positive cells by genotype is depicted for (A) B cells, (B) naı¨ve B cells, (C) non-switched memory B cells and (D) class-
switched memory B cells in the G/G (n = 70), G/T (n = 34) and T/T (n = 12) genotype group. Box-whisker plots represent median, quartiles and
1.5 interquartile range (IQR). rs4810485*T is the multiple sclerosis risk allele. P-value is given for a linear regression of CD40 MFI in function of
the number of T alleles.
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CD14hiCD16+) and in the myeloid subset in untreated
multiple sclerosis patients. We found no evidence of associa-
tion with rs9282641 genotype in any of these cell sets
(Supplementary Figs 13 and 14). In the healthy control sub-
jects we also tested for association of CD86 expression in B
cells and monocytes with rs1920296 and rs2255214, two
other SNPs mapping close to rs9282641 and showing inde-
pendent association with multiple sclerosis (The International
Multiple Sclerosis Genetics Consortium and The Wellcome
Trust Case Control Consortium 2, 2011; The International
Multiple Sclerosis Genetics Consortium, 2013). Again we saw
no association with either SNP in any of these cell subtypes.
CD40 genotype correlates with total
and splice-form specific RNA
expression
To explore the mechanism underlying the CD40 and CD86
genotype–immunophenotype relationship further, we carried
out gene expression analysis in subsets of the study popula-
tion. Based on Gencode version 21 (GRCh38) the gene for
CD86 consists of eight exons, which through alternate spli-
cing give rise to at least nine RNA transcripts (Supplementary
Fig. 5), some of which lack the transmembrane domain (exon
6) and therefore give rise to soluble forms of the molecule
(sCD86) (Jellis et al., 1995). The known CD86 transcripts
show alternative ﬁrst exon usage, and rs9282641 lies within
the 50UTR of the exon 2 starting transcripts. Hence, we
measured sCD86 in serum and assessed expression at the
RNA level in healthy individuals. However, we found no
statistically signiﬁcant association with the rs9282641*G
allele for sCD86 plasma levels nor for any of the four
groups of CD86 transcripts (transmembrane exon 6-contain-
ing transcripts, soluble exon 6-skipping transcripts, exon
1-starting transcripts and exon 2-starting transcripts) in B
cells or monocytes from healthy individuals (Supplementary
Figs 15 and 17).
Multiple CD40 isoforms, representing both membrane-
bound and soluble proteins, have been reported
Figure 2 Association of the CD40 SNP rs4810485 with B cell surface expression of CD40 in multiple sclerosis patients (n = 66).
MFI of CD40 by genotype is depicted for (A) B cells, (B) transitional B cells, (C) naı¨ve B cells, (D) non-switched memory B cells, (E) class-
switched memory B cells, and (F) plasmablasts in the G/G (n = 34), G/T (n = 25) and T/T (n = 7) genotype group. Box-whisker plots represent
median, quartiles and 1.5 IQR. rs4810485*T is the multiple sclerosis risk allele. P-value is given for a linear regression of CD40 MFI in function of
the number of T alleles including batch as covariate.
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(Tone et al., 2001; Eshel et al., 2008). Hence, we addition-
ally measured levels of total CD40 expression as well as
splice-forms lacking exon 5 and/or 6 in PBMCs from the
included untreated multiple sclerosis patients. In line with
ﬂow cytometry data, the multiple sclerosis risk allele
rs4810485*T shows a trend for association with lower
total CD40 expression (P = 0.057). Moreover, the risk
allele differentially affects the relative quantity of each
splice-form compared to total CD40 expression, with
increased proportions of the splice form lacking exon 5
(P = 4.00  107) and decreased proportions of the splice
form lacking exon 6 (P = 0.0036) (Fig. 5). There is a con-
sistent association (P5 0.05) between higher relative
expression of the CD40 isoform lacking exon 5 and
lower expression of full-length CD40 protein on the cell
membrane (CD40 MFI) in overall B cells and in four of
ﬁve B cell subsets (Supplementary Table 2).
CD40 genotype correlates with
downstream interleukin-10
expression
Finally, to investigate the downstream consequences of the
observed genotype–phenotype correlations, we assessed a
panel of cytokines in plasma samples from multiple sclerosis
patients. No signiﬁcant association was observed between
the CD86 rs9282641 genotype and cytokine plasma levels
(P5 0.25). CD40 genotype on the other hand was asso-
ciated with interleukin-10 (IL-10) plasma levels. The IL-10
assay has a dynamic range of 0.03–233pg/ml, a sensitivity
of 0.03 pg/ml, and an r240.99 across technical replicates.
For a subset of n = 17 untreated multiple sclerosis patients,
IL-10 levels were measured from samples at two different
time points, with an average interval of 3 years. Correlation
amongst these different time-point measures in the same
individuals resulted in an r2 = 0.67, indicating relative
intra-individual stability of IL-10 plasma levels over long
periods of time (Supplementary Fig. 18). This is in line
with the high level of interindividual variation, with low
longitudinal variation, which we previously demonstrated
for cellular immune phenotypes (Carr et al., 2016). The
multiple sclerosis risk allele rs4810485*T, associated with
lower CD40 surface expression levels in the ﬂow cytometry
data, corresponded to lower IL-10 levels (Fig. 6).
Discussion
By applying detailed immunophenotyping in untreated mul-
tiple sclerosis patients and healthy controls, we have
demonstrated that cell surface expression of the co-stimu-
latory molecules CD40 and CD86 on B cells is inﬂuenced
by local genetic variants associated with disease susceptibil-
ity, suggesting that B cells contribute to the pathogenesis of
the disease. The fact that the effect of rs4810485 on the
expression of CD40 is seen in all B cell subsets, while the
effect of rs9282641 on CD86 expression is essentially
conﬁned to naı¨ve cells, might reﬂect involvement of a
Figure 3 Association of the CD86 SNP rs9282641 with B cell surface expression of CD86 in healthy controls (n = 135).
Percentage of CD86-positive cells by genotype is depicted for (A) B cells, (B) naı¨ve B cells, (C) non-switched memory B cells and (D) class-
switched memory B cells in the A/A (n = 14), A/G (n = 47) and G/G (n = 74) genotype group. Box-whisker plots represent median, quartiles and
1.5 IQR. rs9282641*G is the multiple sclerosis risk allele. P-value is given for a linear regression of per cent CD86-positive in function of the
number of G alleles.
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ubiquitous enhancer for CD40 expression and an enhancer
with more restricted cell type speciﬁcity for CD86.
Our data in untreated patients and controls indicate a
strong genotype–phenotype correlation for CD40 across B
cell differentiation stages (transitional, naı¨ve, non-switched
memory, switched memory and plasmablasts, with P-values
ranging from 105 to 107) and hence extend a previously
reported association reaching nominal signiﬁcance in over-
all B cells from 86 healthy controls (Field et al., 2015). In
both datasets, the multiple sclerosis risk allele rs4810485*T
is associated with decreased cell surface expression.
Previous analysis of CD40 expression at the RNA level
has generated contradictory results (Jacobson et al., 2005;
Onouchi et al., 2012; Field et al., 2015); however, by using
sensitive droplet digital PCR to measure the levels of alter-
native splice forms, we here demonstrate that transcripts
are differentially affected by genotype. In PBMCs from
untreated multiple sclerosis patients, rs4810485*T is asso-
ciated with a lower proportion of the splice form lacking
exon 6, in line with ﬁndings in B cell lines derived from
healthy controls (Onouchi et al., 2012), and a higher pro-
portion of the splice form lacking exon 5. The alternative
splice-forms lacking exon 6 and exon 5 encode soluble
decoy receptors: the ﬁrst one has antagonistic properties
whereas the second isoform has been reported not to
bind CD40 or act downstream of CD40-CD40L stimula-
tion, but may bind other CD40 ligands (Eshel et al., 2008).
During B cell activation and CD40 upregulation, pre-CD40
mRNA splicing is shifted from predominantly generating
the full-length isoform to reaching higher proportions of
the antagonistic soluble form and this process is thought
to provide a negative feedback-loop (Tone et al., 2001).
Hence, CD40 genetic variation affecting a ubiquitous
CD40 enhancer may at the same time induce this post-
transcriptional regulation process affecting splicing.
Notably, the CD40 SNP is shared across autoimmune
diseases but with opposite effects: the rs4810485*T allele
increases the risk of multiple sclerosis (The Australia and
New Zealand Multiple Sclerosis Genetics Consortium,
2009; Patsopoulos et al., 2011; The International Multiple
Figure 4 Association of the CD86 SNP rs9282641 with B cell surface expression of CD86 in untreated multiple sclerosis
patients (n = 67). Percentage of CD86-positive cells by genotype is depicted for (A) B cells, (B) transitional B cells, (C) naı¨ve B cells, (D) non-
switched memory B cells, (E) class-switched memory B cells and (F) plasmablasts in the A/G (n = 14) and G/G (n = 53) genotype group. Box-
whisker plots represent median, quartiles and 1.5 IQR. rs9282641*G is the multiple sclerosis risk allele. P-value is given for a linear regression of
per cent CD86-positive in function of the number of G alleles with batch as covariate.
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Sclerosis Genetics Consortium and The Wellcome Trust
Case Control Consortium 2, 2011; The International
Multiple Sclerosis Genetics Consortium, 2013) and inﬂam-
matory bowel disease (Jostins et al., 2012) but is protective
against rheumatoid arthritis (Raychaudhuri et al., 2008),
systemic lupus erythematosus (Vazgiourakis et al., 2011),
autoimmune thyroid disease (Tomer et al., 2002) and
Kawasaki disease (Onouchi et al., 2012). CD40 is important
for T cell dependent immunoglobulin class-switching and
germinal centre formation (Kawabe et al., 1994) and plas-
mablast growth and differentiation (Garcia de Vinuesa
et al., 1999). Hence, increased CD40 expression levels on
B cell subsets involved in antibody production, and in par-
ticular the effect on both expression levels and the percen-
tage of CD40-positive plasmablasts that we report for the
ﬁrst time, are consistent with increased susceptibility to
autoimmune diseases involving a strong humoral response
(rheumatoid arthritis; systemic lupus erythematosus; auto-
immune thyroid disease and Kawasaki disease). On the
other hand, CD40 ligation has beneﬁcial effects including
the induction of regulatory T cells (Guiducci et al., 2005)
and the formation and function of IL-10 producing B cells
with immunomodulatory properties (Yanaba et al., 2009).
In the animal model for multiple sclerosis, EAE, the transfer
of regulatory IL-10 producing B cells (B10) into Cd19/
B cell deﬁcient mice reduces EAE severity and reduces auto-
antigen-speciﬁc CD4+ T cell proliferation and pro-inﬂam-
matory cytokine production (Yoshizaki et al., 2012).
However, B10 cells that are CD40 deﬁcient (Cd40/) do
not reduce severity, proliferation or cytokine production.
On the other hand, CD40 stimulation increases the
number of B10 cells (Yoshizaki et al., 2012). A beneﬁcial
role for regulatory B cells has also been described in
humans for the two autoimmune diseases where reduced
CD40 increases susceptibility, namely multiple sclerosis
and inﬂammatory bowel disease (Li et al., 2015, Dooley
et al., 2016). Our current work indeed pinpoints to the
regulatory function of CD40, through downstream IL-10
production, as mechanism of action underlying this associa-
tion, with the risk allele leading to lower CD40 cell surface
expression and lower IL-10 levels.
Our data on expression levels of the CD86 co-stimula-
tory molecule across B cell subsets, from low percentages of
positive cells amongst the naı¨ve B cell subset increasing
over memory B cells to highest levels in plasmablast reﬂect
B cell activation (Liu et al., 1995; Tangye et al., 1998;
Ellyard et al., 2004; Good et al., 2009). CD86 expression
levels on B cells are increased in the CSF compared to the
peripheral blood of multiple sclerosis patients (Fraussen
et al., 2016), possibly reﬂecting the high expression levels
on plasmablasts. We demonstrate that the local multiple
sclerosis risk allele rs9282641*G is associated with a
higher percentage of CD86-positive B cells in untreated
multiple sclerosis patients and controls. The effect appears
strongest in a speciﬁc B cell subset, naı¨ve B cells, again for
both patients and controls. Higher CD86 expression in this
B cell subset has previously been associated with multiple
sclerosis versus controls (Niino et al., 2009; Fraussen et al.,
2016) with relapse versus remission in multiple sclerosis
(Niino et al., 2009), and with a phenotype of high
Figure 5 Association of the CD40 SNP rs4810485 with total CD40 and CD40 alternative splice forms in untreated multiple
sclerosis patients (n = 65). Genotype specific (A) relative quantity of total CD40 expression (spanning exons 1–2) versus housekeeping gene and
relative quantity of alternative CD40 splice-forms lacking (B) exon 5, (C) exons 5–6 and (D) exon 6 compared to relative quantity of total CD40
expression in the G/G (n = 34), G/T (n = 25) and T/T (n = 6) genotype group. Box-whisker plots represent median, quartiles and 1.5 IQR.
rs4810485*T is the multiple sclerosis risk allele. P-value is given for a linear regression of CD40 expression levels in function of the number of Talleles.
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neurodegeneration in multiple sclerosis (Comabella et al.,
2016). Quite how and why changes in the proportion of
naı¨ve B cells expressing CD86 inﬂuence the development of
the disease is not clear. Such a change might simply reﬂect
an enhanced tendency towards activation or perhaps inﬂu-
ence an individual’s ability to generate regulatory T cells
(Reichardt et al., 2007). Given that the expression of CD86
is likely to be essential for B cells undertaking an antigen
presentation role, another possible interpretation of these
ﬁndings is that the multiple sclerosis associated genotype
increases the proportion of B cells undertaking this func-
tion, and that perhaps antigen presentation contributes to
pathogenesis. It is well established that many of the genes
implicated through genetic analysis of multiple sclerosis are
involved in the signalling between antigen presenting cells
and lymphocytes, and it is notable that these associations
are generally stronger for the receptor/ligand from the
antigen presenting cell side of each of such interaction
(Sawcer et al., 2014). This is most evident in the compar-
ison between the very profound class II MHC
associations in multiple sclerosis (Moutsianas et al., 2015)
and the near absence of any notable association with
variation in the regions of the T cell receptor genes.
Within a single genome-wide association study such
differences might simply be assumed to reﬂect the inevitable
random variation in the effect sizes measured for relevant
SNPs. However, the fact that these differences have
been reproduced in large follow-up efforts, such as the
immunochip study (The International Multiple Sclerosis
Genetics Consortium, 2013) raises the possibility that the
differences genuinely reﬂect the relative importance of
antigen presenting cells in the aetiology of multiple
sclerosis.
Our study design combined two independent approaches
with different workﬂows and methodologies each with their
own strengths and limitations. One approach focused on
the extensive investigation of all B cell subsets whereas the
other invested heavily in methodological control of the ﬂow
cytometry and considered a wider range of potentially
relevant genetic variation. Importantly, concordant results
and conclusions were reached in both study populations,
independent of the experimental design, providing mutual
replication for these results.
Limitations of our ex vivo study include the inability to
directly correlate the genotype-dependent CD40 RNA
and protein expression to the increased IL-10 production.
Studies in the animal model of multiple sclerosis, EAE,
have shown that CD40 ablation or stimulation regulates
IL-10-producing B cell number and function, as described
above. Demonstrating the same effects for the more
subtle genotype-dependent expression differences in
humans would require a follow-up study with the develop-
ment of an in vitro model that has the capacity to detect
B cell stimulation effects in the physiological range of
SNPs, possibly through an agonistic CD40 antibody or
co-culture with a T cell line expressing CD40 ligand
(CD154).
Our data indicating that the studied multiple sclerosis
risk SNPs affect the expression of co-stimulatory molecules
on B cells have implications for treatment strategies in mul-
tiple sclerosis. Existing treatments such as interferon-beta
and ﬁngolimod affect CD86 expression in different ways
(Niino et al., 2009; Fraussen et al., 2016)—in line with
the general opposing effects of these treatments on the per-
ipheral immune system (Dooley et al., 2016). However, the
recently completed ACCLAIM clinical trial with abatacept,
blocking CD80-CD86 co-stimulation and approved for
rheumatoid arthritis and juvenile idiopathic arthritis,
failed in multiple sclerosis (Khoury et al., 2017). As both
our genotype data and data on existing treatments (Niino
et al., 2009) indicate cell-subset-speciﬁc effects on CD86
expression in multiple sclerosis, in particular related to
naı¨ve B cells, such subset-speciﬁc effects may underlie
this unexpected outcome. Phase II trials blocking the
CD40-CD40L pathway—currently halted due to throm-
boembolic events (Summers deLuca and Gommerman,
2012)—were initiated on the basis of a beneﬁcial role of
CD40 blockade in EAE (Gerritse et al., 1996; Howard
et al., 1999), accompanied in particular by a reduction in
anti-MOG antibodies (Boon et al., 2001). These animal
model data are in line with the higher-expression allele
increasing risk of autoimmune diseases with a strong
humoral response. Our data in humans, however, suggest
that CD40 blockade may be counter-productive in multiple
sclerosis as it may inhibit beneﬁcial mechanisms such as
IL-10 producing immunomodulatory B cells. We have pre-
viously demonstrated the upregulation of BAFF and transi-
tional B cells as a unique common pathway of current
efﬁcacious multiple sclerosis treatments, shedding new
light on the failure of anti-BAFF trials, which also appeared
promising in EAE (Dooley et al., 2016). Together, these
data highlight the failure of the EAE model to mimic the
B cell component of multiple sclerosis and indicate how
human genotype–immunophenotype data may direct the
development of therapeutic strategies.
Figure 6 Association of the CD40 SNP rs4810485 with
serum IL-10 levels in untreated multiple sclerosis patients
(n = 66). IL-10 levels are measured in the G/G (n = 34), G/T
(n = 25) and T/T (n = 7) genotype group. Box-whisker plots repre-
sent median, quartiles and 1.5 IQR. rs4810485*T is the multiple
sclerosis risk allele. P-value is given for a linear regression of IL-10
levels in function of the number of T alleles.
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